VARIVAX powder + solvent for injection suspension medication leaflet

J07BK01 live attenuated chickenpox vaccine • Antiinfectives for systemic use | Viral vaccines | Varicella zoster vaccines

The live attenuated varicella vaccine is used to prevent chickenpox, a highly contagious viral disease caused by the varicella-zoster virus (VZV). The vaccine contains a weakened form of the virus, which stimulates the immune system to produce antibodies against VZV, providing long-term protection against infection.

The vaccine is administered subcutaneously, usually in two doses, with the first dose given at 12-15 months of age and the second between 4 and 6 years. It is recommended for both children and adults who have not had chickenpox or been previously vaccinated.

Common side effects include redness, pain, or swelling at the injection site, mild fever, and rashes. In rare cases, severe allergic reactions or neurological complications may occur.

The live attenuated varicella vaccine is an effective preventive measure, helping to reduce the incidence of chickenpox and its associated complications, such as secondary bacterial infections and viral pneumonia.

General data about VARIVAX

Substance: live attenuated chickenpox vaccine

Date of last drug list: 01-06-2025

Commercial code: W66309005

Pharmaceutical form: powder + solvent for injection suspension

Quantity: 1

Product type: original

Price: 207.93 RON

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: MERCK SHARP & DOHME B.V. - OLANDA

Holder: MERCK SHARP & DOHME ROMANIA S.R.L. - ROMANIA

Number: 12595/2019/05

Shelf life: 2 years

Pharmaceutical forms available for live attenuated chickenpox vaccine

Other substances similar to live attenuated chickenpox vaccine

Compensation lists for VARIVAX MERCK SHARP DOHME

E2 - Sublist E - section E2 with 100% discount from the reference price

Price

Copayment

Patient

207.93 RON

207.93 RON

0.00 RON